Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated with Sepsis in Patients Undergoing Antimicrobial Treatment
February 12, 2024 08:30 ET
|
HelixBind
Study shows RaPID/BSI assay can accurately identify bloodstream infections associated with sepsis in patients undergoing antimicrobial treatment.
HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize by HHS and Steven & Alexandra Cohen Foundation
February 07, 2024 11:05 ET
|
HelixBind
HelixBind Named a Phase 2 Winner of the LymeX Diagnostics Prize by HHS and Steven & Alexandra Cohen Foundation
HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis
June 17, 2021 08:30 ET
|
HelixBind
BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
August 24, 2020 11:47 ET
|
HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease
July 16, 2020 12:01 ET
|
HelixBind
BOXBOROUGH, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for patients afflicted with invasive microbial infections,...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
June 10, 2020 10:29 ET
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...